What are the responsibilities and job description for the Principal Scientist, Early In Process Analytics, Mammalian Expression Technology CoE position at GlaxoSmithKline?
Principal Scientist, Early In-Process Analytics, Mammalian Expression Technology CoE
Scroll down for a complete overview of what this job will require Are you the right candidate for this opportunity
At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. R&D is committed to discovering and delivering transformational vaccines and medicines to prevent and change the course of disease.
We believe the Greater Boston area is an important hub for the biotech and pharma industry, which is why we’ve invested in growing our footprint and expanding our R&D space in Cambridge, with a primary focus on additional state-of-the-art lab space. Here, we will bring together talent and expertise, building upon GSK’s long history of vaccine development, to create globally leading viral capabilities and cutting-edge vaccines technologies, as we add to our robust portfolio targeting infectious diseases at every stage of life.
In the plan to create a new hub for mRNA-based vaccine discovery and CHO recombinant protein vaccine early development in Cambridge, we are building new laboratories that will be focused on the development of state-of-the-art methods that will be supporting deep product understanding, process and product development, as well as testing of pre-clinical and clinical samples for new mRNA and CHO protein-based vaccines. Situated in Cambridge-based hub, Mammalian Expression Technology Center of Excellence (MET CoE), Technical Research & Development, GSK Vaccines R&D is responsible for the development of CHO based production cell lines, next-gen cell line engineering and baseline upstream process for innovative recombinant protein / adjuvanted vaccine projects and platforms.
Key Responsibilities :
As a Principal Scientist, Early In-Process Analytics, Mammalian Expression Technology CoE, you will be expected to take on the main core responsibilities as listed below :
- Drive the design, development and implementation of in-process analytical methods (content, potency and process, and product-related impurities) to support cell line and early process development projects as well as next-gen cell line engineering.
- Technical leader / Subject matter expertise representing DS to collaborate proactively with preclinical / discovery teams and late-stage in-process analytic group to support antigen selection and early product understanding workflows to enable swift CMC onboarding and transferring.
- Lead the assessment and implementation of novel in-process analytical techniques to support acceleration of project delivery and CMC submissions.
The candidate is also expected to spend few months (from 3 to 6 months) within the first year in Rockville, MD (Washington DC area) to support and ensure a smooth transition of the methods and the knowhow to the new laboratories in Cambridge.
Basic Qualifications :
Preferred Qualifications :
Why GSK?
GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together – so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns – as an organisation where people can thrive. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory / immunology and oncology).
Our success absolutely depends on our people. While getting ahead of disease together is about our ambition for patients and shareholders, it’s also about making GSK a place where people can thrive. We want GSK to be a place where people feel inspired, encouraged and challenged to be the best they can be. A place where they can be themselves – feeling welcome, valued, and included. Where they can keep growing and look after their wellbeing. So, if you share our ambition, join us at this exciting moment in our journey to get Ahead Together.
J-18808-Ljbffr
